Filing summary
Entity mismatch: Request metadata names Decoy Therapeutics Inc., but the supplied Form 10-Q is for Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX). This summary covers Salarius’s unaudited quarter and nine months ended September 30, 2021.
Business context
Salarius is a clinical-stage biopharmaceutical company developing seclidemstat (SP-2577), an LSD1 inhibitor, for cancers including Ewing sarcoma and other FET-rearranged sarcomas. The company had no approved products or product-sale revenue and reported an accumulated deficit of $28.1 million.
Financial results
| Metric | Three months ended Sept. 30, 2021 | Three months ended Sept. 30, 2020 | Nine months ended Sept. 30, 2021 | Nine months ended Sept. 30, 2020 |
|---|---|---|---|---|
| Grant revenue | $0 | $1.38 million | $1.84 million | $3.75 million |
| Research and development | $2.02 million | $1.80 million | $5.85 million | $4.89 million |
| General and administrative | $1.73 million | $1.33 million | $4.66 million | $4.89 million |
| Net loss | $3.74 million | $1.72 million | $8.66 million | $5.58 million |
| Basic and diluted loss per share | $0.08 | $0.10 | $0.22 | $0.40 |
Loss margins are not meaningful because revenue is grant-based and there were no product sales. Revenue declined as CPRIT grant funding available for reimbursement was exhausted; no grant revenue was recognized in the third quarter. R&D expense rose, which management attributed to personnel, clinical-trial and laboratory costs. Quarterly G&A increased, while nine-month G&A decreased versus 2020, partly because prior-year severance costs did not recur.
- Cash and liquidity: Cash and cash equivalents were $31.9 million at September 30, 2021, versus $11.1 million at December 31, 2020. Working capital was $33.6 million. CPRIT grants receivable was $2.1 million, down from $3.9 million.
- Cash flow: Nine-month operating cash use was $7.5 million, compared with $8.9 million in 2020. Financing provided $28.3 million, mainly from equity offerings and warrant exercises; cash increased by $20.8 million.
- Debt and equity: The $477,028 note payable outstanding at year-end 2020 was repaid; no note payable was reported at September 30, 2021. Total liabilities were $1.6 million. Equity offerings and warrant exercises materially increased shares outstanding; 45.2 million shares were outstanding at September 30, 2021.
Outlook, risks and notable items
Management said cash on hand and collection of the CPRIT receivable were expected to fund anticipated operating and capital needs through completion of current clinical trials in 2022 and beyond. It also said substantial additional capital would be needed to continue operations and development; future financing is not assured and equity financing could dilute shareholders. The CPRIT grant term extends to May 31, 2022, but the company said it had expended all currently available grant funds and met the matching requirement.
The Ewing sarcoma study was amended to include SP-2577 with topotecan and cyclophosphamide; the expansion could enroll up to 30 Ewing sarcoma patients and up to 30 patients with other FET-rearranged sarcomas. An investigator-initiated study in myelodysplastic syndromes or chronic myelomonocytic leukemia was also noted. These are development plans, not evidence of established efficacy or approval.
Management reported minimal COVID-19 disruption to date but warned of possible trial-enrollment delays, supply-chain disruption, added costs and reduced access to capital. The filing noted a November 1, 2021 closing share price of $0.85 and described Nasdaq minimum-bid-price delisting risk. The company reported no material legal proceedings and concluded disclosure controls were effective.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Salarius Pharmaceuticals, not Decoy Therapeutics.
- Track CPRIT receivable collection, grant status and any remaining eligibility or repayment obligations.
- Assess cash use, trial costs, clinical milestones and whether the stated cash runway remains achievable.
- Review subsequent capital raises, share dilution, warrant overhang and Nasdaq listing compliance.
- Check later clinical-trial data and enrollment progress; the filing’s efficacy statements are preliminary and forward-looking.